fluorouracil has been researched along with Exanthem in 23 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)." | 9.19 | Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014) |
| "Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 9.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 9.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| " He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are called FOLFOX regimen for short." | 7.96 | Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report. ( Huang, J; Huang, Z; Jiang, C; Liu, Z; Zheng, W; Zhu, X, 2020) |
| "Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)." | 5.19 | Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014) |
| "Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 5.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 5.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 5.11 | Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. ( Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN, 2004) |
| " He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are called FOLFOX regimen for short." | 3.96 | Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report. ( Huang, J; Huang, Z; Jiang, C; Liu, Z; Zheng, W; Zhu, X, 2020) |
| "Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival." | 3.73 | Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006) |
| "Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor." | 2.87 | EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. ( Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S, 2018) |
| "Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al." | 2.84 | Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017) |
| "Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491)." | 2.45 | Analysis of dermatologic events in patients with cancer treated with lapatinib. ( Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW, 2009) |
| "To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC)." | 1.72 | Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. ( Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Rosati, G | 1 |
| Corsi, D | 1 |
| Avallone, A | 1 |
| Brugnatelli, S | 1 |
| Dell'Aquila, E | 1 |
| Cinausero, M | 1 |
| Aprile, G | 1 |
| Cicero, G | 1 |
| Carlomagno, C | 1 |
| Colombo, A | 1 |
| Rapisardi, S | 1 |
| Pinto, C | 1 |
| Reggiardo, G | 1 |
| Bilancia, D | 1 |
| Soueidy, C | 1 |
| Skaff, S | 1 |
| Stephan, F | 1 |
| Kattan, J | 1 |
| Huang, J | 1 |
| Jiang, C | 1 |
| Liu, Z | 1 |
| Zheng, W | 1 |
| Zhu, X | 1 |
| Huang, Z | 1 |
| Hernandez-Aragues, I | 1 |
| Baniandrés-Rodríguez, O | 1 |
| Avilés-Izquierdo, JA | 1 |
| Vilas-Boas, PT | 1 |
| Hofheinz, RD | 1 |
| Lorenzen, S | 1 |
| Trojan, J | 1 |
| Ocvirk, J | 1 |
| Ettrich, TJ | 1 |
| Al-Batran, SE | 1 |
| Schulz, H | 1 |
| Homann, N | 1 |
| Feustel, HP | 1 |
| Schatz, M | 1 |
| Kripp, M | 1 |
| Schulte, N | 1 |
| Tetyusheva, M | 1 |
| Heeger, S | 1 |
| Vlassak, S | 1 |
| Merx, K | 1 |
| Aranda, E | 1 |
| García-Alfonso, P | 1 |
| Benavides, M | 1 |
| Sánchez Ruiz, A | 1 |
| Guillén-Ponce, C | 1 |
| Safont, MJ | 1 |
| Alcaide, J | 1 |
| Gómez, A | 1 |
| López, R | 1 |
| Manzano, JL | 1 |
| Méndez Ureña, M | 1 |
| Sastre, J | 1 |
| Rivera, F | 1 |
| Grávalos, C | 1 |
| García, T | 1 |
| Martín-Valadés, JI | 1 |
| Falcó, E | 1 |
| Navalón, M | 1 |
| González Flores, E | 1 |
| Ma García Tapiador, A | 1 |
| Ma López Muñoz, A | 1 |
| Barrajón, E | 1 |
| Reboredo, M | 1 |
| García Teijido, P | 1 |
| Viudez, A | 1 |
| Cárdenas, N | 1 |
| Díaz-Rubio, E | 1 |
| Que, SKT | 1 |
| Compton, LA | 1 |
| Schmults, CD | 1 |
| Rubovszky, G | 1 |
| Láng, I | 1 |
| Ganofszky, E | 1 |
| Horváth, Z | 1 |
| Juhos, E | 1 |
| Nagy, T | 1 |
| Szabó, E | 1 |
| Szentirmay, Z | 1 |
| Budai, B | 1 |
| Hitre, E | 1 |
| Dranitsaris, G | 1 |
| Lacouture, ME | 2 |
| Piotrowski, MJ | 1 |
| Gunn, H | 1 |
| Kirby, J | 1 |
| Ali, L | 1 |
| Helm, K | 1 |
| Schimanski, CC | 1 |
| Staib, F | 1 |
| Göhler, T | 1 |
| Hebart, H | 1 |
| Heike, M | 1 |
| Neise, M | 1 |
| Rudi, J | 1 |
| Geer, T | 1 |
| Dingeldein, G | 1 |
| Lang, C | 1 |
| Ehscheidt, P | 1 |
| Flohr, T | 1 |
| Josten, KM | 1 |
| Karthaus, M | 1 |
| Schmittel, A | 1 |
| Wierecky, J | 1 |
| Boller, E | 1 |
| Indorf, M | 1 |
| Wörns, MA | 1 |
| Galle, PR | 1 |
| Moehler, M | 1 |
| Laabs, SM | 1 |
| Koehler, M | 1 |
| Sweetman, RW | 1 |
| Preston, AJ | 1 |
| Di Leo, A | 1 |
| Gomez, HL | 1 |
| Salazar, VM | 1 |
| Byrne, JA | 1 |
| Koch, KM | 1 |
| Blackwell, KL | 1 |
| Raoul, JL | 1 |
| Van Laethem, JL | 1 |
| Peeters, M | 1 |
| Brezault, C | 1 |
| Husseini, F | 1 |
| Cals, L | 1 |
| Nippgen, J | 1 |
| Loos, AH | 1 |
| Rougier, P | 1 |
| Seront, E | 1 |
| Marot, L | 1 |
| Coche, E | 1 |
| Gala, JL | 1 |
| Sempoux, C | 1 |
| Humblet, Y | 1 |
| Xiao, YY | 2 |
| Liu, F | 2 |
| Chen, ZP | 2 |
| Ping, QN | 2 |
| Xu, BH | 1 |
| Jiang, ZF | 1 |
| Chua, D | 1 |
| Shao, ZM | 1 |
| Luo, RC | 1 |
| Wang, XJ | 1 |
| Liu, DG | 1 |
| Yeo, W | 1 |
| Yu, SY | 1 |
| Newstat, B | 1 |
| Preston, A | 1 |
| Martin, AM | 1 |
| Chi, HD | 1 |
| Wang, L | 1 |
| Powers, R | 1 |
| Gordon, R | 1 |
| Roberts, K | 1 |
| Kovach, R | 1 |
| Messersmith, WA | 1 |
| Laheru, DA | 1 |
| Senzer, NN | 1 |
| Donehower, RC | 1 |
| Grouleff, P | 1 |
| Rogers, T | 1 |
| Kelley, SK | 1 |
| Ramies, DA | 1 |
| Lum, BL | 1 |
| Hidalgo, M | 1 |
| Brennan, DD | 1 |
| Farrelly, C | 1 |
| Cooney, R | 1 |
| Norris, S | 1 |
| McEniff, N | 1 |
| Gotlib, V | 1 |
| Khaled, S | 1 |
| Lapko, I | 1 |
| Mar, N | 1 |
| Saif, MW | 1 |
| Ueki, H | 1 |
| Namba, M | 1 |
| Imoto, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Crisaborole Ointment, a Phosphodiesterase 4 (PDE4) Inhibitor, for the Topical Treatment of Cetuximab-Related Skin Toxicity Among Metastatic Colorectal Cancer Patients：A Prospective, Single-arm, Phase II Clinical Trial[NCT06118047] | Phase 2 | 33 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-l[NCT01161316] | Phase 2 | 194 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer[NCT00508274] | Phase 3 | 52 participants (Actual) | Interventional | 2007-07-18 | Terminated (stopped due to Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A partial response requires a decrease of 30% or more, complete response requires all target lesions disappear, Progression requires an increase of at least 20%, and Stable disease falls in between these two. All responses have a repeat assessment to confirm the response." (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 57.7 |
Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 8.18 |
PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 6.34 |
Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment. (NCT00508274)
Timeframe: at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 53.55 |
Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 4.07 |
On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 4276 days (treatment duration ranged from 13 - 4246 days) for Lapatinib and 3384 days (treatment duration ranged form 8 - 3354 days) for Capecitabine. Total deaths was collected from study start to study end (LPLV). (NCT00508274)
Timeframe: up to 4276 days for Lapatinib/up to 3384 days for Capecitabine (on-treatment), approx. 12 years (all collected deaths)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Total Deaths | On-treatment Deaths | |
| Lapatinib + Capecitabine | 11 | 2 |
Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months
| Intervention | participants (Number) | |
|---|---|---|
| Participants with any site of relapse | Participants with CNS disease as first site of relapse | |
| Lapatinib + Capecitabine | 17 | 2 |
2 reviews available for fluorouracil and Exanthem
| Article | Year |
|---|---|
JAAD Grand Rounds quiz: Red-brown hyperkeratotic papules in a 69-year-old man.
Topics: Aged; Biopsy, Needle; Disease Progression; Exanthema; Fluorouracil; Follow-Up Studies; Humans; Immun | 2015 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2009 |
8 trials available for fluorouracil and Exanthem
| Article | Year |
|---|---|
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi | 2018 |
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas | 2018 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast N | 2014 |
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant | 2017 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecit | 2011 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protoc | 2004 |
13 other studies available for fluorouracil and Exanthem
| Article | Year |
|---|---|
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neopl | 2022 |
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu | 2023 |
Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Exanthema; Fluorouracil; Humans; Leucovorin; Male; M | 2020 |
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil.
Topics: Adult; Biopsy, Needle; Carcinoma, Squamous Cell; Cohort Studies; Databases, Factual; Diagnosis, Diff | 2019 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
[Microemulsion-based gel of fluorouracil for transdermal delivery].
Topics: Administration, Cutaneous; Animals; Antimetabolites, Antineoplastic; Dioctyl Sulfosuccinic Acid; Dru | 2010 |
[Water in oil microemulsions containing NaCl for transdermal delivery of fluorouracil].
Topics: Administration, Cutaneous; Animals; Antimetabolites, Antineoplastic; Dioctyl Sulfosuccinic Acid; Dru | 2011 |
Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil.
Topics: Administration, Cutaneous; Drug Eruptions; Exanthema; Fluorouracil; Hand Dermatoses; Humans; Immunos | 2012 |
Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery.
Topics: Abdomen; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Arteries; Chemoembolization, | 2005 |
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2006 |
[Drug exanthema caused by a new 5-fluorouracil derivative].
Topics: Chemical Phenomena; Chemistry; Exanthema; Female; Fluorouracil; Humans; Middle Aged; Tegafur | 1980 |
Feasibility of adjuvant chemotherapy for breast cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1997 |